查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970813

癌症幹細胞市場－全球產業規模、佔有率、趨勢、機會與預測：按作用機制、癌症類型、地區和競爭格局分類，2021-2031年

Cancer Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Mode Of Action (Targeted Cancerous Stem Cells, Stem Cell Usage Against Cancer), By Cancer Forms, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症幹細胞市場預計將從 2025 年的 37.9 億美元成長到 2031 年的 61.3 億美元，複合年成長率為 8.34%。

癌症幹細胞是一類具有自我更新和分化能力的特殊癌細胞亞群，是腫瘤發生和轉移的主要促進因素。該市場的成長主要受全球惡性腫瘤發生率上升以及對有效應對腫瘤復發治療方法的迫切需求所驅動。此外，腫瘤學研發資金的增加也加速了專門針對這些頑固細胞群的新型藥物的研發。

市場概覽
預測期 2027-2031
市場規模：2025年 37.9億美元
市場規模：2031年 61.3億美元
複合年成長率：2026-2031年 8.34%
成長最快的細分市場 胸部
最大的市場 北美洲

儘管取得了這些進展，但市場發展仍面臨許多重大障礙，特別是臨床試驗的高昂成本以及分離特定生物標記的技術難題。然而，日益加重的疾病負擔持續推動先進治療方法的需求。美國癌症協會預測，到2024年，光是美國就將新增約200萬例癌症病例。如此高的發生率強烈表明，亟需有效的癌症幹細胞靶向策略來克服治療抗藥性帶來的挑戰，並改善患者的預後。

市場促進因素

全球癌症發生率和盛行率的不斷上升是癌症幹細胞市場成長的主要促進因素，也因此迫切需要先進的治療性介入。由於傳統治療方法往往無法根除休眠的幹細胞亞群，惡性腫瘤負擔的加重與預防轉移和復發的治療方法需求的日益成長直接相關。大量患者需要有效的長期護理，凸顯了這種緊迫性。根據世界衛生組織（世衛組織）2024年2月發布的《全球癌症負擔》報告，2022年全球新增癌症病例估計為2,000萬例。展望未來，美國癌症協會預測，到2050年，全球癌症病例將增加至3,500萬例，這意味著對創新型幹細胞標靶技術的需求將持續成長。

同時，公共和私人研發投資的激增正在加速幹細胞生物學向臨床應用的轉化。分離和鑑定癌症幹細胞的複雜性要求對先進的基因組分析和藥物篩檢平台投入大量資金。資金的增加將使製藥公司和學術機構能夠克服靶向這些頑強細胞的技術障礙。這種資金投入已在政府的主要預算撥款中充分體現。例如，美國國家癌症研究所（NCI）將在2024年獲得約72.2億美元的撥款，用於支持廣泛的腫瘤學研究舉措，從而創造一個有利於癌症幹細胞療法和精準醫療發展的環境。

市場挑戰

臨床試驗的巨額成本是全球癌症幹細胞市場擴張的主要障礙。開發有效針對癌症幹細胞的療法需要複雜且長期的研究設計，以檢驗其不僅能縮小腫瘤，還能預防腫瘤復發和轉移。這個漫長的過程需要巨額資金，顯著增加了生物製藥開發公司的資本風險。因此，這種財務負擔阻礙了中小型生物技術公司進入市場，迫使它們優先考慮最具商業性前景的資產，並延緩了創新型癌症幹細胞標靶藥物的整體開發平臺。

腫瘤學領域的最新數據凸顯了這次經濟障礙的巨大影響。根據美國臨床腫瘤學會（ASCO）估計，到2024年，僅藥物一項，進行一項III期癌症臨床試驗的中位數成本就約為2.449億美元。如此驚人的成本提高了准入門檻，並直接阻礙了市場擴張，因為它限制了能夠成功從臨床前研究過渡到監管核准的新治療方法數量。

市場趨勢

從傳統的2D培養到3D類器官模型的轉變，正在從根本上改變癌症幹細胞領域的臨床前藥物評估。標準的單層培養往往無法複製複雜的腫瘤微環境，而3D系統則保留了研究幹細胞特性和評估抗藥性所必需的細胞異質性。這種更真實地模擬人體組織的能力，正推動著對先進建模技術的大量投資，旨在降低臨床失敗率。例如，在2024年1月的資金籌措公告中，Carcinotech公司宣布已獲得420萬英鎊的資金，用於擴展其3D列印腫瘤建模平台，旨在提高針對複雜癌症結構的資金籌措的準確性，並加快有效治療方法的上市速度。

同時，人工智慧和深度學習的融合正在簡化癌症幹細胞的識別和靶向抑制劑的開發。計算平台的速度遠超傳統方法，能夠分析龐大的基因組資料集，進而預測抗藥性機制並最佳化分子結構。這種高效的運作促進了領先的製藥公司之間圍繞數位生物學的合作，旨在提高研發管線的準確性。例如，禮來公司於2024年1月宣布與Isomorphic Labs建立策略夥伴關係，同意支付4,500萬美元的預付款，以獲得使用人工智慧技術進行多標靶藥物發現的權利。這凸顯了製藥業對計算創新在應對疑難雜症方面日益成長的依賴。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球癌症幹細胞市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 作用機轉（標靶癌症幹細胞（CSCs），幹細胞在癌症治療的應用）
    • 癌症類型（乳癌、血癌、肺癌）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美癌症幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲癌症幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區癌症幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲癌症幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲癌症幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球癌症幹細胞市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc.
  • AbbVie, Inc.
  • Lonza Group Ltd
  • The Menarini Group
  • Miltenyi Biotec BV & Co. KG
  • PromoCell GmbH
  • MacroGenics, Inc.
  • STEMCELL Technologies Canada Inc.
  • Sino Biological, Inc.
  • Lineage Cell Therapeutics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27649

The Global Cancer Stem Cells Market is projected to expand from a valuation of USD 3.79 Billion in 2025 to USD 6.13 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.34%. Cancer stem cells represent a unique subpopulation of tumor cells endowed with the ability to self-renew and differentiate, acting as the primary drivers behind tumorigenesis and metastasis. The growth of this market is largely fueled by the rising global prevalence of malignancies and the critical need for therapies capable of effectively addressing tumor recurrence. Furthermore, increased financial support for oncology research is accelerating the development of novel agents specifically designed to target these persistent cell populations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.79 Billion
Market Size 2031USD 6.13 Billion
CAGR 2026-20318.34%
Fastest Growing SegmentBreast
Largest MarketNorth America

Despite this progress, market advancement encounters significant hurdles, particularly regarding the substantial costs linked to clinical trials and the technical difficulties involved in isolating specific biomarkers. Nevertheless, the escalating disease burden continues to drive the demand for sophisticated solutions. According to the American Cancer Society, projections for 2024 indicated approximately two million new cancer cases within the United States alone. This high incidence rate underscores the imperative need for effective cancer stem cell targeting strategies to enhance patient outcomes and surmount challenges related to therapeutic resistance.

Market Driver

The escalating global incidence and prevalence of cancer acts as a primary catalyst for the growth of the cancer stem cells market, creating an urgent demand for advanced therapeutic interventions. Since conventional treatments frequently fail to eradicate dormant stem cell subpopulations, the rising burden of malignancy directly correlates with an increased need for therapies designed to prevent metastasis and relapse. This urgency is highlighted by the sheer volume of patients requiring effective long-term care; according to the World Health Organization's 'Global Cancer Burden' report from February 2024, there were an estimated 20 million new cancer cases worldwide in 2022. Looking ahead, the American Cancer Society predicts that global cancer cases will rise to 35 million by 2050, ensuring a sustained trajectory of demand for stem cell-targeted innovations.

Simultaneously, a surge in public and private research and development investments is expediting the translation of stem cell biology into clinical applications. The complexity of isolating and characterizing cancer stem cells requires substantial capital for sophisticated genomic analysis and drug screening platforms. Enhanced funding enables pharmaceutical companies and academic institutions to overcome the technical barriers associated with targeting these resilient cells. This financial commitment is evident in major government allocations; for instance, the National Cancer Institute was allocated a budget of approximately $7.22 billion in 2024 to support broad oncology research initiatives, fostering an environment conducive to breakthroughs in cancer stem cell therapies and precision medicine development.

Market Challenge

The exorbitant costs associated with clinical trials constitute a significant obstacle to the expansion of the Global Cancer Stem Cells Market. Developing therapeutics that effectively target cancer stem cells requires complex and prolonged study designs to validate their ability to prevent tumor recurrence and metastasis, rather than merely reducing tumor mass. These extended timelines necessitate massive financial resources, significantly increasing the capital risk for biopharmaceutical developers. Consequently, this financial burden discourages market entry for smaller biotechnology entities and compels companies to prioritize only the most commercially viable assets, thereby slowing the overall pipeline of innovative stem cell-targeting agents.

The magnitude of this economic barrier is highlighted by recent data from the oncology sector. According to the American Society of Clinical Oncology, the mean drug cost alone for conducting a Phase III cancer clinical trial was estimated to be approximately $244.9 million in 2024. This staggering expense creates a high barrier to entry, directly hampering the market's expansion by limiting the number of novel therapies that can successfully navigate the transition from preclinical research to regulatory approval.

Market Trends

The transition from traditional 2D cultures to 3D organoid models is fundamentally transforming preclinical drug evaluation within the cancer stem cell sector. While standard monolayers often fail to replicate the complex tumor microenvironment, 3D systems preserve the cellular heterogeneity essential for studying stemness and evaluating drug resistance. This capability to better mimic human tissue is driving significant investment into advanced modeling technologies aimed at reducing clinical failure rates. For example, Carcinotech announced in a January 2024 funding release that it secured £4.2 million to expand its 3D-printed tumor model platform, designed to improve the accuracy of testing therapeutics against complex cancer architectures and accelerate the delivery of effective treatments to market.

In parallel, the integration of artificial intelligence and deep learning is streamlining the identification of cancer stem cells and the development of targeted inhibitors. Computational platforms are increasingly capable of analyzing massive genomic datasets to predict resistance mechanisms and optimize molecular structures significantly faster than traditional methods. This operational efficiency has prompted major pharmaceutical alliances centered on digital biology to enhance pipeline precision. Illustrating this trend, Eli Lilly and Company announced a strategic partnership in January 2024, committing an upfront payment of $45 million to Isomorphic Labs to utilize their artificial intelligence technologies for multi-target drug discovery, highlighting the industry's growing reliance on computational innovation to address difficult-to-treat pathologies.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • AbbVie, Inc.
  • Lonza Group Ltd
  • The Menarini Group
  • Miltenyi Biotec B.V. & Co. KG
  • PromoCell GmbH
  • MacroGenics, Inc.
  • STEMCELL Technologies Canada Inc.
  • Sino Biological, Inc.
  • Lineage Cell Therapeutics, Inc.

Report Scope

In this report, the Global Cancer Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Stem Cells Market, By Mode Of Action

  • Targeted Cancerous Stem Cells (CSCs)
  • Stem Cell Usage Against Cancer

Cancer Stem Cells Market, By Cancer Forms

  • Breast
  • Blood
  • Lung

Cancer Stem Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Stem Cells Market.

Available Customizations:

Global Cancer Stem Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Stem Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Mode Of Action (Targeted Cancerous Stem Cells (CSCs), Stem Cell Usage Against Cancer)
    • 5.2.2. By Cancer Forms (Breast, Blood, Lung)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cancer Stem Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Mode Of Action
    • 6.2.2. By Cancer Forms
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cancer Stem Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Mode Of Action
        • 6.3.1.2.2. By Cancer Forms
    • 6.3.2. Canada Cancer Stem Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Mode Of Action
        • 6.3.2.2.2. By Cancer Forms
    • 6.3.3. Mexico Cancer Stem Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Mode Of Action
        • 6.3.3.2.2. By Cancer Forms

7. Europe Cancer Stem Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Mode Of Action
    • 7.2.2. By Cancer Forms
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cancer Stem Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Mode Of Action
        • 7.3.1.2.2. By Cancer Forms
    • 7.3.2. France Cancer Stem Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Mode Of Action
        • 7.3.2.2.2. By Cancer Forms
    • 7.3.3. United Kingdom Cancer Stem Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Mode Of Action
        • 7.3.3.2.2. By Cancer Forms
    • 7.3.4. Italy Cancer Stem Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Mode Of Action
        • 7.3.4.2.2. By Cancer Forms
    • 7.3.5. Spain Cancer Stem Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Mode Of Action
        • 7.3.5.2.2. By Cancer Forms

8. Asia Pacific Cancer Stem Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Mode Of Action
    • 8.2.2. By Cancer Forms
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cancer Stem Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Mode Of Action
        • 8.3.1.2.2. By Cancer Forms
    • 8.3.2. India Cancer Stem Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Mode Of Action
        • 8.3.2.2.2. By Cancer Forms
    • 8.3.3. Japan Cancer Stem Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Mode Of Action
        • 8.3.3.2.2. By Cancer Forms
    • 8.3.4. South Korea Cancer Stem Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Mode Of Action
        • 8.3.4.2.2. By Cancer Forms
    • 8.3.5. Australia Cancer Stem Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Mode Of Action
        • 8.3.5.2.2. By Cancer Forms

9. Middle East & Africa Cancer Stem Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Mode Of Action
    • 9.2.2. By Cancer Forms
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cancer Stem Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Mode Of Action
        • 9.3.1.2.2. By Cancer Forms
    • 9.3.2. UAE Cancer Stem Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Mode Of Action
        • 9.3.2.2.2. By Cancer Forms
    • 9.3.3. South Africa Cancer Stem Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Mode Of Action
        • 9.3.3.2.2. By Cancer Forms

10. South America Cancer Stem Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Mode Of Action
    • 10.2.2. By Cancer Forms
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Stem Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Mode Of Action
        • 10.3.1.2.2. By Cancer Forms
    • 10.3.2. Colombia Cancer Stem Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Mode Of Action
        • 10.3.2.2.2. By Cancer Forms
    • 10.3.3. Argentina Cancer Stem Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Mode Of Action
        • 10.3.3.2.2. By Cancer Forms

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cancer Stem Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie, Inc.
  • 15.3. Lonza Group Ltd
  • 15.4. The Menarini Group
  • 15.5. Miltenyi Biotec B.V. & Co. KG
  • 15.6. PromoCell GmbH
  • 15.7. MacroGenics, Inc.
  • 15.8. STEMCELL Technologies Canada Inc.
  • 15.9. Sino Biological, Inc.
  • 15.10. Lineage Cell Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer